Best Information Technology Companies To Own In Right Now

Best Information Technology Companies To Own In Right Now: Momenta Pharmaceuticals Inc.(MNTA)

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the characterization and process engineering of complex molecules. These complex molecules include proteins; polypeptides; and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development and commercialization of generic versions of complex drug products, as well as for the discovery and development of novel drugs. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes. The company?s products also include M356, an abbreviated new drug application under FDA review, is a generic version of Copaxone for the reduction of the frequency of relapses in patients with relapse-remitting multiple sclerosis; M118, which completed a Phase IIa clinical trial as an anticoagulant for acute coronary syndromes; and M402, a novel HSPG-based product candidate that is in preclinical development as a potential anti-cancer agent. It has collaboration agreements with Sandoz AG and Sandoz Inc. to develop and commercialize Enoxaparin sodium injection. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Advisors' Opinion:

• [By Maxx Chatsko]

  Building momentum
  It may not seem too impressive on the surface, but Momenta Pharmaceuticals (NASDAQ: MNTA  ) has the makings of a game-changing biotech company. The company has developed a novel platform that greatly speeds the development and characterization of complex biological compounds. Unlike more traditional small molecules, therapeutic proteins are massive molecules whose exact chemical structure and makeup can vary from o! ne production method to the other. Simple folds of subunits within the protein can drastically affect its efficacy and toxicity.

• [By Maxx Chatsko]

  Shares of biotech innovator Momenta Pharmaceuticals (NASDAQ: MNTA  ) entered into a nosedive in early June, but quickly recovered after analysts at UBS AG upgraded the stock from "neutral" to "buy." I don't put any faith in analyst projections -- and neither should you -- but I do see value in the company's technology. Momenta has developed a platform for analyzing and characterizing complex molecules that could significantly reduce R&D costs and development times of drugs in the pipeline. If you're an investor looking for a biotech company with boatloads of potential, you may be wondering about adding Momenta to your portfolio. Fool contributor Maxx Chatsko breaks down that decision for investors in the following video.

source from Top Penny Stocks For 2015:http://www.topstocksforum.com/best-information-technology-companies-to-own-in-right-now-3.html